US84833T1034 - Common Stock - After market: 1.92 +0.02 (+1.05%)
NASDAQ:SPRO (2/3/2023, 6:59:52 PM)+0.07 (+3.83%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-14 2022-11-14/amc | Earnings (Next) | 03-29 2023-03-29 |
Ins Owners | 1.77% | Inst Owners | 38.39% |
Market Cap | 98.37M | Shares | 51.78M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 80 |
IPO | 11-02 2017-11-02 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant (MDR) bacterial infections, and rare diseases where there is unmet medical and patient need. Its lead product candidate, tebipenem pivoxil hydrobromide (tebipenem HBr) is designed to be the first oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. Its pipeline also includes SPR720 and SPR206. SPR720 is designed to be the first oral treatment for non-tuberculous mycobacterial (NTM) infection. SPR206 is a direct acting intravenous (IV) administered polymyxin analogue developed from its potentiator platform to treat MDR Gram-negative bacterial infections within the hospital.
SPERO THERAPEUTICS INC
675 Massachusetts Ave Ste 14
Cambridge MASSACHUSETTS 02139
P: 18572421600.0
CEO: Ankit Mahadevia
Employees: 41
Website: https://sperotherapeutics.com/
CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical...
Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million...
Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common...
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...
Here you can normally see the latest stock twits on SPRO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: